Isotopia Molecular Imaging ltd

Isotopia is a global leader in innovative radiopharmaceuticals, driving advancements in medical diagnostics and therapeutic solutions. We specialize in developing, producing, and distributing radiopharmaceutical technologies that transform patient care and support medical research globally. Our Comprehensive Radiopharmaceutical Portfolio: Theranostics products: • Lu-177 chloride (non-carrier added and carrier added) Diagnostic and Imaging products: • Isoportrace®- PSMA-11 kit for Ga-68 labeling for prostate cancer imaging Nuclear Pharmacy products: • PET and SPECT products. Global Operations: 1. Israel: • HEADQUARTERS & LU-177 PRODUCTION SITE: Our global headquarters we are dedicated to the production of Lutetium-177 (Lu-177), a critical radionuclide for cancer therapies. This site ensures consistent quality and supply for our global customer base. • ASEPTIC PLANT & CMO SERVICES: Our aseptic plant in Israel specializes in the production of cold kits and offers comprehensive Contract Manufacturing Organization (CMO) services, including the manufacture of sterile and lyophilized products for clinical trials and commercial applications. 2. Austria: GMP-COMPLIANT LU-177 PRODUCTION: Our Austrian facility adheres to Good Manufacturing Practice (GMP) standards, ensuring high-quality production of Lu-177 for therapeutic use, particularly in cancer treatment. 3. United States: LU-177 ISOTOPIA PRODUCTION: Supporting North American operations, this site is focused on producing FDA-compliant Lu-177 Isotopia, meeting the needs of our customers across the region. Our Mission: Isotopia is dedicated to advancing medical breakthroughs with high-quality radiopharmaceuticals that enhance diagnostic accuracy and therapeutic outcomes worldwide. With over 160 professionals and 3 production sites, including 2 in Israel, we ensure a reliable, compliant supply of radiopharmaceuticals globally.